November 3, 2017 — VitalConnect Inc. announced the fourth and final Series C closing, bringing the total Series C round of funding to $38 million. The round was led by MVM and Baxter Ventures. This funding will help VitalConnect in launching the VitalConnect Platform and VitalPatch wearable biosensor in hospitals and outpatient settings across the nation.
VitalConnect combines the sophisticated VitalPatch biosensor with its comprehensive software platform. The VitalPatch is the smallest and lightest Class 2 medical device approved by the U.S. Food and Drug Administration (FDA), according to the company, that measures eight different vital signs continuously and in real time. The band-aid-like biosensor patch is single-use and fully disposable.
VitalConnect launched in 2011 and raised Series A funding of $12 million that year, and subsequently closed a $22 million Series B round in 2016.
For more information: www.vitalconnect.com